Notably, the PARP1 inhibitor Olaparib significantly reduces tumor burden in Nudt13VillKO mice, implying that CRC patients with low NUDT13 protein levels may benefit from Olaparib treatment. Here, NUDT13 is linked to colorectal carcinoma.